Would you consider administration of neoadjuvant anthracycline for cT2N1 ER+/PR+/HER2- patients given that this may be excessive for N1 disease, or do you wait until nodal status is confirmed on surgical pathology?

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic

How do you stage and evaluate premenopausal patients with >= cN1 ER+ PR+ HER2- breast cancer prior to surgery to avoid this pitfall?

Answer from: Medical Oncologist at Academic Institution

Yes, I would consider anthracycline-based therapy in cT2N1M0 HR+/HER2-negative breast cancer. The ABC trial, the only large-scale trial testing anthracycline specifically in HER-negative cases, showed only a marginal benefit in disease-free survival (not quite statistically significant), and appeare...

Comments

Medical Oncologist at University of Wisconsin Hospital & Clinics
I would also add that the addition of anthracyclin...

Medical Oncologist at St Jude Heritage Medical Group
Does the most recent long-term follow-up ABC trial...

Related Questions